Blurbs

Provention Bio (PRVB) Receives a Buy from SVB Securities

SVB Securities analyst Thomas Smith maintained a Buy rating on Provention Bio (PRVBResearch Report) today and set a price target of $19.00. The company’s shares closed last Friday at $8.08.

Smith covers the Healthcare sector, focusing on stocks such as Provention Bio, Keros Therapeutics, and Immunic. According to TipRanks, Smith has an average return of -4.3% and a 39.10% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Provention Bio with a $19.33 average price target, implying a 139.23% upside from current levels. In a report released on November 18, Jefferies also maintained a Buy rating on the stock with a $22.00 price target.

See today’s best-performing stocks on TipRanks >>

PRVB market cap is currently $704.5M and has a P/E ratio of -5.19.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.

Read More on PRVB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More